Institution
Ipsen
Company•Paris, France•
About: Ipsen is a company organization based out in Paris, France. It is known for research contribution in the topics: Lanreotide & Somatostatin. The organization has 1259 authors who have published 1501 publications receiving 33753 citations.
Topics: Lanreotide, Somatostatin, Population, Receptor, Ginkgo biloba
Papers published on a yearly basis
Papers
More filters
••
University College London1, Charité2, University of Warmia and Mazury in Olsztyn3, Medical University of Vienna4, Charles University in Prague5, Cedars-Sinai Medical Center6, Autonomous University of Barcelona7, Western General Hospital8, Catholic University of the Sacred Heart9, Ipsen10, University of Paris11
TL;DR: Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2 (Ki-67 <10%) and the therapeutic effect in predefined subgroups was generally consistent with that in the overall population.
Abstract: Background Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited. Methods We conducted a randomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreotide in patients with advanced, well-differentiated or moderately differentiated, nonfunctioning, somatostatin receptor–positive neuroendocrine tumors of grade 1 or 2 (a tumor proliferation index [on staining for the Ki-67 antigen] of <10%) and documented disease-progression status. The tumors originated in the pancreas, midgut, or hindgut or were of unknown origin. Patients were randomly assigned to receive an extended-release aqueous-gel formulation of lanreotide (Autogel [known in the United States as Depot], Ipsen) at a dose of 120 mg (101 patients) or placebo (103 patients) once every 28 days for 96 weeks. The primary end point was progression-free survival, defined as the time to disease progression (according to the Response Evaluation Criteria in Solid Tumors, version 1.0) or death. Secondary end points included overall survival, quality of life (assessed with the European Organization for Research and Treatment of Cancer questionnaires QLQ-C30 and QLQ-GI.NET21), and safety. Results Most patients (96%) had no tumor progression in the 3 to 6 months before randomization, and 33% had hepatic tumor volumes greater than 25%. Lanreotide, as compared with placebo, was associated with significantly prolonged progression-free survival (median not reached vs. median of 18.0 months, P<0.001 by the stratified log-rank test; hazard ratio for progression or death, 0.47; 95% confidence interval [CI], 0.30 to 0.73). The estimated rates of progression-free survival at 24 months were 65.1% (95% CI, 54.0 to 74.1) in the lanreotide group and 33.0% (95% CI, 23.0 to 43.3) in the placebo group. The therapeutic effect in predefined subgroups was generally consistent with that in the overall population, with the exception of small subgroups in which confidence intervals were wide. There were no significant betweengroup differences in quality of life or overall survival. The most common treatment-related adverse event was diarrhea (in 26% of the patients in the lanreotide group and 9% of those in the placebo group). Conclusions Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2 (Ki-67 <10%). (Funded by Ipsen; CLARINET ClinicalTrials.gov number, NCT00353496; EudraCT 2005-004904-35.)
1,305 citations
••
TL;DR: Many free radical scavengers have produced promising results in relation to AD, as has desferrioxamine-an iron-chelating agent- and antiinflammatory drugs and estrogens, which also have an antioxidant effect.
1,095 citations
••
TL;DR: The importance of regular monitoring of sUA in order to tailor gout treatment was highlighted by data from this study showing that patients with sUA levels ⩾360 μmol/l (⩾6 mg/dl) had an increased risk of gout flares.
Abstract: Objective: To investigate and compare the prevalence, comorbidities and management of gout in practice in the UK and Germany. Methods: A retrospective analysis of patients with gout, identified through the records of 2.5 million patients in UK general practices and 2.4 million patients attending GPs or internists in Germany, using the IMS Disease Analyzer. Results: The prevalence of gout was 1.4% in the UK and Germany. Obesity was the most common comorbidity in the UK (27.7%), but in Germany the most common comorbidity was diabetes (25.9%). The prevalence of comorbidities tended to increase with serum uric acid (sUA) levels. There was a positive correlation between sUA level and the frequency of gout flares. Compared with those in whom sUA was 530 μmol/l ( >9 mg/dl) in the UK and Germany, respectively (p Conclusions: The prevalence of gout in practice in the UK and Germany in the years 2000–5 was 1.4%, consistent with previous UK data for 1990–9. Chronic comorbidities were common among patients with gout and included conditions associated with an increased risk for cardiovascular disease, such as obesity, diabetes and hypertension. The importance of regular monitoring of sUA in order to tailor gout treatment was highlighted by data from this study showing that patients with sUA levels ⩾360 μmol/l (⩾6 mg/dl) had an increased risk of gout flares.
443 citations
••
TL;DR: Modulation of hypothalamic fatty acid metabolism specifically in the VMH in response to ghrelin is a physiological mechanism that controls feeding, and decreasing AMPK activity in the ventromedial nucleus of the hypothalamus (VMH) is sufficient to inhibit gh Relin's effects on FAS expression and feeding.
437 citations
••
TL;DR: PBR is an indispensable element of the steroidogenic machinery and its presence is vital for hCG-induced steroidogenesis by Leydig cells.
384 citations
Authors
Showing all 1259 results
Name | H-index | Papers | Citations |
---|---|---|---|
Donald Kufe | 121 | 681 | 49343 |
Christophe Baudouin | 74 | 553 | 22068 |
Andrea Giustina | 73 | 443 | 23125 |
Mauricio R. Delgado | 71 | 257 | 21138 |
James A. Levine | 68 | 250 | 14958 |
Jennifer A. Chan | 67 | 230 | 20594 |
Marion K Campbell | 65 | 252 | 19109 |
Andrew L. Lewis | 57 | 213 | 10538 |
Jürgen Drewe | 55 | 208 | 11752 |
Eiji Oki | 50 | 541 | 9479 |
Thomas Binz | 50 | 107 | 10718 |
Pierre Braquet | 50 | 368 | 8503 |
Bernard Ducommun | 48 | 158 | 9065 |
Andrew A. Butler | 46 | 119 | 11333 |
Arpad Tosaki | 46 | 201 | 6224 |